TNFSF11 and bone metastasis: Molecules like biphosphonates (particularly ZA) or RANKL antibodies (denosumab), through their ability to interfere with osteoclastogenesis, represent the current standard therapeutic option for patients with bone metastasis [25], [33], [34], [35], [36].